Dr. Ferrer BioPharma Named Finalist in 2025 MEDICA Start-Up Competition for MoxieLink App

When thousands of innovators gather in Düsseldorf this November for MEDICA 2025, a South Florida company will be among those in the spotlight. Dr. Ferrer BioPharma has been named a finalist in the Health Apps category of the MEDICA Start-up Competition for MoxieLink, earning a place among the Top 15 Medical Start-ups of the Year.

MoxieLink, the company’s HIPAA-compliant digital platform, unites patient data and uses AI to streamline provider workflow, helping reduce avoidable hospital readmissions and improve outcomes.

The MoxieLink app displayed on a mobile phone and laptop. Image Credit: The Moxie Health Group

Selected from more than 230 submissions worldwide, the Hallandale Beach–based biotech company was recognized for its operational platform that enhances diagnosis and personalizes patient care — a technology that integrates digital precision into respiratory health management.

“Being named a finalist at MEDICA is an honor that reflects our team’s dedication to advancing respiratory care through science, compassion, and collaboration,” said Dr. Gustavo Ferrer, the company’s founder and CEO. “We’re proud to represent the innovation coming from our research and to share our mission to help patients breathe better with leaders from across the global healthcare industry.”

Taking Innovation to the International Stage

As part of the competition, Dr. Ferrer BioPharma will present its platform during the MEDICA Start-up Competition Pitch and Award Ceremony on November 18 at the MEDICA Innovation Forum in Düsseldorf, Germany. The company will also exhibit throughout the four-day event, joining thousands of healthcare professionals, researchers, and industry leaders to showcase advances in medical technology.

Held annually, MEDICA is recognized as the world’s largest medical trade fair, attracting exhibitors from nearly 70 nations and more than 8,500 participants at its Innovation Forum. The start-up competition honors early-stage companies driving the future of medicine through breakthroughs in artificial intelligence, diagnostics, robotics, and digital health.

A Growing Force in Respiratory Health

For Dr. Ferrer BioPharma, the recognition marks another milestone in its mission to transform how respiratory diseases are diagnosed and treated. Founded by Dr. Ferrer, a pulmonologist and critical care specialist, the company combines decades of clinical experience with modern biotechnology to deliver treatments that go beyond symptom relief — empowering patients to manage their respiratory health more effectively.

From its roots in South Florida to the international stage, Dr. Ferrer BioPharma continues to push the boundaries of respiratory medicine — driven by a mission summed up in two words: “Breathe Better."

To learn more about MoxieLink, click here.